Te­va gets a mixed bag of PhI­II da­ta as it lines up against a (bet­ter?) Neu­ro­crine ri­val for tar­dive dysk­i­ne­sia

Four months af­ter the FDA re­ject­ed Te­va’s “break­through” drug SD-809 for treat­ing chorea as­so­ci­at­ed Hunt­ing­ton’s dis­ease, the phar­ma group is back with a batch of mixed Phase III da­ta on tar­dive dysk­i­ne­sia, the in­vol­un­tary move­ments as­so­ci­at­ed with the de­gen­er­a­tive dis­ease. And once again Te­va is up­beat about the re­sults, say­ing the da­ta clears the way to a new mar­ket­ing pitch lat­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER